Breast Cancer :: Local cells affect tamoxifen sensitivity
Breast cancer cells that express estrogen receptor (ER) can be treated with tamoxifen only as long as they remain sensitive to the drug.
Breast cancer cells that express estrogen receptor (ER) can be treated with tamoxifen only as long as they remain sensitive to the drug.
Researchers have identified loss of Fiblin-2 as a marker of breast cancer progression since the protein is expressed by normal breast cells but lost in breast cancer cell lines and invasive breast tumors.
New studies of a blood protein recently identified at Johns Hopkins, early prostate cancer antigen-2 (EPCA-2), may change the way men are screened for prostate cancer – a disease that kills tens of thousands of men every year.
The BreastScreen Australia Program has been increasingly successful in detecting breast cancer over the last ten years, according to the eighth national monitoring report for the BreastScreen Australia Program, launched today by the Hon Tony Abbott, Minister for Health and Ageing at the Police & Community Youth Club (PCYC) in Coffs Harbour.
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today statistically significant results with BEMA Fentanyl in cancer patients with breakthrough pain in its pivotal Phase III efficacy clinical trial for the product.
A simple modification in an anti-cancer treatment currently in clinical trials substantially improves the drug?s effectiveness and reduces side effects in experiments with laboratory mice, researchers are reporting in an article scheduled for the May 16 edition of ACS? Bioconjugate Chemistry, a bi-monthly journal.
Analysis of three genetic mechanisms that cause nonsmall cell lung cancer might explain why East Asians respond better than other ethnic groups to a certain type of chemotherapy, a team led by UT Southwestern Medical Center researchers has found.
Researchers at the Ireland Cancer Center of University Hospitals Case Medical Center have developed methods for treating lung cancer cells that have become resistant to new anti-cancer agents.
The following is a transcript of remarks by President Bush at the signing of H.R. 1132, the National Breast and Cervical Cancer Early Detection Program Reauthorization Act:
A team of scientists from the University of Massachusetts Amherst have created a kind of molecular nose that uses nanoparticle-based sensors to sniff out and identify proteins.